Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 150
- Registration Number
- NCT06233942
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT06218888
HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Li Xiao Wei
- Target Recruit Count
- 54
- Registration Number
- NCT06210334
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Yangpu, Shanghai, China
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 780
- Registration Number
- NCT06206733
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, China
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06197438
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
- Conditions
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 76
- Registration Number
- NCT06167785
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 41
- Registration Number
- NCT06134193
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-13
- Target Recruit Count
- 60
- Registration Number
- NCT06124378
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT06118658
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Guo Xufeng
- Target Recruit Count
- 73
- Registration Number
- NCT06056336
- Locations
- 🇨🇳
Shanghai chest hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.